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Abstract 
Background: Gold nanoparticles (AuNPs) are promising candidates to design the next generation NP‑based drug 
formulations specifically treating maternal, fetal or placental complications with reduced side effects. Profound knowl‑
edge on AuNP distribution and effects at the human placental barrier in dependence on the particle properties and 
surface modifications, however, is currently lacking. Moreover, the predictive value of human placental transfer mod‑
els for NP translocation studies is not yet clearly understood, in particular with regards to differences between static 
and dynamic exposures. To understand if small (3–4 nm) AuNPs with different surface modifications (PEGylated versus 
carboxylated) are taken up and cross the human placental barrier, we performed translocation studies in a static 
human in vitro co‑culture placenta model and the dynamic human ex vivo placental perfusion model. The samples 
were analysed using ICP‑MS, laser ablation‑ICP‑MS and TEM analysis for sensitive, label‑free detection of AuNPs.
Results: After 24 h of exposure, both AuNP types crossed the human placental barrier in vitro, although in low 
amounts. Even though cellular uptake was higher for carboxylated AuNPs, translocation was slightly increased for 
PEGylated AuNPs. After 6 h of perfusion, only PEGylated AuNPs were observed in the fetal circulation and tissue 
accumulation was similar for both AuNP types. While PEGylated AuNPs were highly stable in the biological media and 
provided consistent results among the two placenta models, carboxylated AuNPs agglomerated and adhered to the 
perfusion device, resulting in different cellular doses under static and dynamic exposure conditions.
Conclusions: Gold nanoparticles cross the human placental barrier in limited amounts and accumulate in placental 
tissue, depending on their size‑ and/or surface modification. However, it is challenging to identify the contribution of 
individual characteristics since they often affect colloidal particle stability, resulting in different biological interaction 
in particular under static versus dynamic conditions. This study highlights that human ex vivo and in vitro placenta 
models can provide valuable mechanistic insights on NP uptake and translocation if accounting for NP stability and 
non‑specific interactions with the test system.
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Background
Gold nanoparticles (AuNPs) exhibit unique character-
istics such as surface plasmon resonance, high stability 
in aqueous solutions, simple synthesis and modification 
of their surface properties, production with narrow size 
distributions and excellent compatibility with biological 
tissues [1, 2]. Therefore, they are widely explored in high 
technology applications such as organic photovoltaics, 
electronic conductors or catalysis as well as in the medi-
cal sector as potential tool in diagnostics, treatment and 
imaging [1–3].
NPs used as drug carriers demonstrate a promising 
opportunity for targeted treatment. Especially for preg-
nant women, it would be of great advantage to specifi-
cally treat only maternal, placental or fetal complications, 
avoiding potentially harmful side effects in the other 
compartments [4, 5]. However, before such a NP-based 
drug delivery strategy can be introduced to pregnant 
patients, its safety needs to be proven and the NPs need 
to be tailored in a specific way to steer their biodistribu-
tion and placental translocation in the expecting mother. 
Knowledge on how to control placental NP transfer via 
their physico-chemical properties or surface modifica-
tions is slowly emerging [4, 6, 7]. For instance, placen-
tal NP uptake and translocation has been shown to be 
dependent on particle size, surface modification and 
material composition [6]. Recently, specific targeting of 
NPs to the pregnant uterus was achieved to treat fetal 
growth restriction in mice [7]. Liposomes were loaded 
with a vasodilator and linked with a vascular targeting 
peptide, which enhanced accumulation of these NPs in 
the uterine vasculature and drug efficacy [7].
For AuNPs, studies investigating materno-fetal trans-
location and/or impact of the NPs on the placental bar-
rier function and pregnancy are still rare and mostly 
done in pregnant rodents. However, since the placenta 
is probably the most species specific organ, it is impor-
tant to confirm potential placental accumulation and 
transfer in human placenta models [8–10]. In humans, 
materno-fetal exchange occurs across four layers, namely 
the endothelial cells of the fetal capillary walls, the sur-
rounding fetal stroma containing Hofbauer cells, a layer 
of mononucleated cytotrophoblasts (CT) and the multi-
nucleated syncytiotrophoblast (ST) facing the maternal 
blood when the uteroplacental circulation is established 
after the first trimester of pregnancy. With ongoing ges-
tation, the fetal capillaries multiply and migrate towards 
the thinning ST. At the same time, the CT cells flatten 
and partially disappear, resulting in a reduction of the 
barrier thickness to around 2–4 µm at term [11, 12].
In pregnant rats, Semmler-Behnke et  al. [13] have 
shown that a substantial higher amount of 1.4 nm nega-
tively charged, radio-labelled AuNPs were found in the 
placentas and in the amniotic fluid after intravenous 
injection compared to larger AuNPs (18 nm and 80 nm). 
However, only 1.4 and 18 nm AuNPs were found in the 
fetus, indicating either a transcellular entry of the AuNPs 
and/or a materno-fetal translocation via transtrophoblas-
tic channels [13]. A study of Tsyganova et  al. [14] con-
firmed a placental translocation of PEGylated AuNPs (5 
and 30 nm) after intravenous injection in pregnant rats, 
but could not verify a size-dependent transfer. In mice, 
Yang et  al. [15] demonstrated that fetal accumulation 
of AuNPs is dependent on their surface modification 
and the stage of pregnancy. In particular, substantially 
less uptake of 13  nm citrate-capped AuNPs in fetal tis-
sues has been found compared to ferritin- or PEGylated-
modified AuNPs in the same size. AuNP internalization 
was strongly reduced, when pregnant mice were exposed 
later than 11.5 days after successful mating (post embry-
onic day 11.5) [15]. 20 and 50 nm AuNPs intravenously 
injected on day 16 and 17 of gestation were found to 
accumulate in mouse placenta and maternal livers with-
out detectable AuNP transfer to the fetal side [16]. No 
signs of toxicity were observed in placental, maternal 
and fetal tissue [16]. First studies on placental transfer of 
AuNPs using human models showed that 10 and 15 nm 
PEGylated-AuNPs did not cross the placental barrier 
after 6  h of ex  vivo placental perfusion or a confluent 
layer of BeWo trophoblast cells after 48  h of exposure 
[17]. This is in apparent contradiction to most of the 
available studies in pregnant rodents, which observed 
placental transfer of small AuNPs (< approx. 20  nm) 
including PEGylated NPs [13–15]. Moreover, studies at 
other biological barriers such as the lung, also described 
a size-dependent translocation of AuNPs [18]. In gen-
eral, only small percentages (below 2%) of the applied 
AuNPs have been shown to cross the alveolar barrier, 
however, significantly higher transfer rates were observed 
both in vitro and in vivo for very small AuNPs (< approx. 
10 nm) [18–20]. Clearly, there is a need to better under-
stand AuNP distribution at the human placental barrier, 
in particular, on the impact of particle size and surface 
modification on placental tissue uptake and materno-
fetal transfer.
In this regard, we have previously found that 4 nm car-
boxylated AuNPs were taken up to a higher extent into 
the trophoblast layer of in vitro human placental co-cul-
ture microtissues (MTs) compared to 3  nm PEGylated 
AuNPs or larger (13–14 nm) particles of both modifica-
tions [21]. However, while 4 nm carboxylated AuNPs pre-
dominantly accumulated in the trophoblast layer, 3  nm 
PEGylated AuNPs penetrated into the fibroblastic core of 
the placental MTs raising the question whether these NPs 
could eventually overcome the human placental barrier 
[21]. Therefore, the aim of this study was to assess the 
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uptake and translocation of small (3–4 nm) AuNPs with 
different surface modifications (PEGylate versus sodium 
carboxylate) at the human placental barrier. Since the 
bioavailable doses and uptake kinetics of NPs can be 
affected by the agglomeration/sedimentation behavior of 
NPs [22, 23] and the dynamic microenvironment [24], a 
further aim of the study was to investigate colloidal sta-
bility of the AuNPs in different biological media and to 
compare uptake and translocation in static and dynamic 
conditions. Hence, translocation studies were performed 
using a static human in vitro co-culture placenta model 
with tight monolayers of placental trophoblast cells 
(human choriocarcinoma cells; BeWo) and endothelial 
cells (human placental venous endothelial cells; HPEC-
A2) cultivated on either side of a microporous membrane 
[25] as well as a dynamic human ex  vivo placental per-
fusion model [26]. Uptake and translocation of AuNPs 
was investigated using laser ablation inductively coupled 
plasma mass spectrometry (LA-ICP-MS), sector-field-
ICP-MS (SF-ICP-MS) and transmission electron micros-
copy (TEM). The agglomeration behavior of the AuNPs 
in the different culture media was monitored by small-
angle X-ray scattering (SAXS).
Methods
Gold nanoparticles (AuNPs)
The AuNPs used in this study were provided within the 
EU FP7 Nanosolutions project and have been extensively 
characterized in our previous study (see Muoth et al. [21] 
for details on AuNP synthesis and characterization and 
Table  1 for a summary of the characteristics). Briefly, 
the AuNPs used in this study are 4 nm sodium carboxy-
late AuNPs (Au-4-COONa) and 3  nm PEGylate AuNPs 
(Au-3-PEG). Additional characterization was performed 
including zeta potential measurements of the AuNPs. 
100 µg/mL AuNP suspensions were prepared in endothe-
lial cell medium (EM) or perfusion medium (PM) (stock 
suspensions were sonicated for 5  min before addition) 
and zeta potential was immediately determined at 25 °C 
using a Zetasizer device (Nanoseries, Nano-ZS90, Mal-
vern, Worcestershire, UK). Suspensions were measured 
in disposable folded capillary cells (DTS 1070; Malvern 
Instruments Ltd., Worcestershire, UK) with 2 min equili-
bration time and five consecutive measurements (with at 
least 10 and maximum of 100 runs).
Small angle X‑ray scattering (SAXS)
The agglomeration of NPs in nanoscale has been studied 
by SAXS experiments. A Nanostar SAXS device (Brucker 
AXS GMBH, Karlsruhe, Germany) equipped with a 
microfocus X-ray source (Cu Kα radiation; 0.154  nm 
wavelength) and MONTEL optics providing a point-
focused beam diameter of about 300  µm was used. A 
VÅNTEC-2000, Xe-based gaseous avalanche detector, 
capable of photon counting with 0.5  s temporal resolu-
tion was used to record the 2-dimensional scattering pat-
terns. Suspensions of 50 µg/mL Au-4-COONa and 25 µg/
mL Au-3-PEG in EM or ultrapure water (0 h, 6 h, 24 h) 
as well as 25 µg/mL suspensions of both NPs in PM (0 h, 
6 h) were incubated at 37 °C/5%  CO2 in Eppendorf tubes 
or 24 well plates under static conditions. Pictures and 
light microscopic images (Primovert, Zeiss, Feldbach, 
Switzerland) of the suspensions were taken for a quali-
tative assessment of NP sedimentation, prior to X-ray 
studies. For SAXS measurements, suspensions (exclud-
ing the pellet) were transferred into quartz capillaries of 
1.5 mm in outer diameter (Hilgenberg GmbH, Malsfeld, 
Germany). The capillaries were vacuum tightened using 
wax sealing. The scattering profiles of empty and water 
filled capillaries were obtained under the same condi-
tions. A semi-transparent beam stop enabled normaliza-
tion of the curves and subtraction of background noise. 
The instrument was operated at sample to detector dis-
tances of about 107 cm providing access to the minimum 
scattering vector modulus [q = (4π/λ) sin(θ), where 2θ 
is the scattering angle] of 0.06 nm−1. The 2-D scattering 
patterns for each sample were recorded 6 times, each 
over an acquisition time of 20  min and then averaged. 
Subsequently, the patterns were azimuthally integrated 
to achieve the 1-D scattering profiles, represented by 
the scattering intensity as a function of scattering vector 
modulus. All SAXS experiments were performed at room 
temperature (RT) after incubation in different media at 
37 °C. The data analysis has been performed by the use of 
generalized indirect Fourier transformation [27, 28] ena-
bling us to achieve the pair-distance distribution function 
(PDDF). From these data, the average radius of gyra-
tion as a quantitative measure of particle size has been 
identified.
Table 1 AuNP characteristics
Data shown as mean ± SD
TEM transmission electron microscopy, ICP-OES inductively coupled plasma 
optical emission spectroscopy, SD standard deviation
a According to [21]
Au‑3‑PEG NPs Au‑4‑COONa NPs
TEM: primary particle size (nm)a 3.5 ± 1.2 4.5 ± 1.5
Zeta potential in  H2O (mV)
a − 16.5 ± 3 − 28.8 ± 0.4
Zeta potential in EM (mV) − 9.4 ± 1.4 − 8.5 ± 0.8
Zeta potential in PM (mV) − 6.8 ± 0.7 − 9.1 ± 0.4
Surface functionalization SH‑PEG(550)CH3 SH‑(CH2)10‑COONa
ICP‑OES: Au content (%)a 76.98 38.38
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Dynamic light scattering (DLS)
The hydrodynamic diameter of the NPs was measured in 
100 µg/mL AuNP suspensions in EM, PM and ultrapure 
 H2O at 37  °C for 0, 6 and 24 h, respectively. Just before 
measurement, the Zetasizer device (Nanoseries, Nano-
ZS90, Malvern, Worcestershire, UK) equipped with 
the standard 633  nm laser was set to 37  °C and the 
pre-heated suspension was added to the cuvette (UV-
transparent disposable; Sarstedt Ag + Co, Nümbre-
cht, Germany) followed by the addition of the required 
amounts of NPs (stock suspensions were sonicated for 
5 min before addition) and short mixing. The experiment 
was started immediately and the first measurement was 
considered as timepoint “0 h”. The measurement duration 
was set to automatic mode without delays and the meas-
urement angle was 90°. The actual temperature of the NP 
suspension in the cuvette was recorded beforehand over 
3 h using a temperature data logger (MSR 145 B4, MSR 
Electronics GmbH, Seuzach, Switzerland) and was deter-
mined to lie between 33.6 and 35.0 °C instead of 37.0 °C.
Cell culture and in vitro barrier formation
HPEC-A2 cells (SV40-transformed microvascular human 
placental venous endothelial cells) and the human pla-
cental choriocarcinoma cell line BeWo b30 were provided 
by Prof. G. Desoye [Department of Obstetrics and Gyne-
cology, Medical University Graz, Graz, Austria (with per-
mission from Prof. P. Friedl, Institute of Biochemistry, 
Technical University Darmstadt, Darmstadt, Germany)] 
and Prof. Dr. Ursula Graf-Hausner [Zurich University 
of Applied Science (with permission from Dr. Alan L. 
Schwartz, Washington University School of Medicine, 
MO, USA)], respectively. General cell cultivation condi-
tions of HPEC-A2 cells and BeWo cells as well as mon-
olayer and co-culture formation were done as described 
previously [25]. Briefly, polycarbonate  Transwell® inserts 
(pore size 3.0  µm, growth area 1.12  cm2, apical volume 
0.5  mL, basolateral volume 1.5  mL;  Corning®, Sigma-
Aldrich, Buchs, Switzerland) were pre-coated with 50 µg/
mL human placental collagen IV (Sigma-Aldrich, Buchs, 
Switzerland) for 1  h at 37  °C/5%  CO2. Monolayer for-
mation was obtained by seeding either 1.5 × 105 BeWo 
cells on the apical side or 1 × 105 HPECs on the baso-
lateral side of the membrane. For the co-culture, HPECs 
were cultivated on the basolateral side for 2  h followed 
by seeding BeWo cells on the apical side. Cells were cul-
tivated for 3  days at 37  °C/5%  CO2 in endothelial cell 
growth medium MV supplemented with 1% penicillin/
streptomycin (pen/strep, Gibco, Luzern, Switzerland) 
and SupplementMix according to the manufacturer’s 
guide (PromoCell, Heidelberg, Germany; further referred 
to as EM) under static conditions (medium change after 
48 h).
In vitro translocation of AuNPs
Co-cultures as well as monolayers (HPECs or BeWo cells 
on the basolateral or apical side of the insert, respec-
tively) were cultivated for 3 days. To determine placental 
translocation in vitro, fresh EM was given to the basolat-
eral chamber and 50  µg/mL of Au-4-COONa (19.2  µg/
mL Au) or 25  µg/mL Au-3-PEG NPs (19.2  µg/mL Au) 
were applied apically. Cultures were then further incu-
bated for 24 h at 37  °C/5%  CO2 under static conditions. 
The transepithelial electrical resistance (TEER) was 
measured before and after the treatment to ensure bar-
rier formation before the experiment and to determine 
a potential influence of the AuNPs on barrier integrity 
after 24 h. At the end of the treatment, apical and baso-
lateral supernatants were collected and membranes were 
kept in fresh pre-warmed EM for TEER measurement. 
Membranes were cut off from the holder with a scalpel 
and all samples were stored for further ICP-MS analysis 
at 4 °C. Samples were also taken from the AuNP working 
suspensions and EM of each experiment to determine Au 
concentration at the beginning of the experiment (0 h).
Ex vivo translocation of AuNPs
Placentas from uncomplicated term pregnancies were 
obtained after caesarean section at the Kantonsspital and 
the Hirslanden Klinik Stephanshorn in St. Gallen (Swit-
zerland). The project was approved by the local ethics 
committee, performed in accordance with the principles 
of the Declaration of Helsinki and written informed con-
sent was given by the expecting mothers prior to deliv-
ery. The ex vivo placental perfusions were performed in 
a dually perfused, closed system as described before [26]. 
The perfusion medium (further referred to as PM) con-
sisted of M199 tissue culture medium, which was diluted 
with Earl’s buffer (1:2) and further supplemented with 
glucose (1  g/L), bovine serum albumin (BSA; 10  g/L), 
dextran 40 (10 g/L), sodium heparin (2500 IU/L), amoxi-
cillin (250  mg/L) and sodium bicarbonate (2.2  g/L; 
medium and all supplements were obtained from Sigma-
Aldrich, Buchs, Switzerland). A perfusion was consid-
ered successful if: (1) the pre-perfusion of the tissue 
showed no leakage, (2) the leakage (fetal to maternal) was 
less than 4  mL/h during the translocation experiment 
and (3) the pH stayed constant during the experiment 
(7.2–7.4). After establishing the system, Au-4-COONa 
and Au-3-PEG were added to the maternal chamber to 
obtain a final concentration of 25  µg/mL. Maternal and 
fetal samples were taken at 0, 0.25, 0.5, 1, 2, 3, 4, 5 and 
6 h of perfusion and analyzed immediately for pH levels 
using a blood gas analyzer (Epocal Inc., Ottawa, Canada). 
Afterwards, supernatants were stored at − 20 °C for fur-
ther ICP-MS analysis. In addition, placental tissue sam-
ples were taken before and after perfusion and stored at 
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− 20 °C for ICP-MS analysis as well as in 4% paraformal-
dehyde (PFA; Sigma-Aldrich, Buchs, Switzerland) at RT 
for LA-ICP-MS analysis.
Transmission electron microscopy (TEM)
TEM was conducted to investigate AuNP internalization 
in BeWo cells. Therefore, cells were cultivated on inserts 
for 3  days as described above and treated with 50  µg/
mL Au-4-COONa or 25  µg/mL Au-3-PEG for 24  h at 
37  °C and 5%  CO2. Cells were detached from 11 inserts 
per condition (without NPs, Au-3-PEG, Au-4-COONa) 
using 0.5% Trypsin–EDTA, pelleted by centrifugation 
(200 g, 5 min) and sucked up into a capillary tube (Leica-
Microsystems). Cells enriched in the capillaries were 
immediately fixed in 3% glutaraldehyde in 0.1 M sodium 
cacodylate buffer and washed in 0.2 M sodium cacodylate 
buffer. After a post-fixation step in 2% osmium tetroxide 
in 0.1  M sodium cacodylate buffer, samples were dehy-
drated through a graded ethanol series followed by ace-
tone and finally embedded in Epon resin (Sigma-Aldrich, 
Buchs, Switzerland). Ultrathin sections were contrasted 
with 2% uranyl acetate and lead citrate (Reynolds 1963) 
before imaged in a Zeiss EM 900 (Carl Zeiss Microscopy 
GmbH, Germany) at 80 kV.
Sector field‑inductively coupled plasma‑mass 
spectrometry (SF‑ICP‑MS)
To determine the Au content of the ex vivo samples, 1 g 
placental tissue (taken before and after each perfusion) 
was homogenized in 3 mL perfusion medium using a Tis-
sueRuptor (Qiagen, Hilden, Germany). Samples of the 
maternal and fetal solution (each 250  µL) and homog-
enized tissue (~ 250  µL corresponding to 83.3  mg tis-
sue) were digested in 0.6  mL concentrated nitric acid 
and 1.8  mL hydrochloric acid (both NORMATOM, 
VWR Chemicals, Vienna, Austria) using a microwave 
(turboWAVE Inert, MLS GmbH, Leutkirch, Germany). 
In  vitro samples (50–200  µL of supernatants or mem-
branes) were digested in HCL and nitric acid (1:2 ratio to 
sample) for 3 days at RT. Processed samples were further 
diluted using ultrapure water. Au content was determined 
by SF-ICP-MS (Element 2, Thermo Finnigan, Bremen, 
Germany) with external calibration ranging from 0 to 
50  µg/L. Rhenium was added to the ex  vivo samples as 
internal standard. The isotope 197Au determined in low 
resolution was used for quantification. The minimum 
detection limits of 197Au were 0.041  µg/L (ex vivo) and 
0.016 µg/L (in vitro) (3*SD). Therefore, approx. 0.0052% 
(Au-3-PEG NPs) and 0.0085% (Au-4-COONa NPs) of the 
initial dose (ID) could have been detected ex vivo in the 
fetal chamber and 0.014% of the ID in vitro on the baso-
lateral side after 24 h.
Laser ablation‑inductively coupled plasma‑mass 
spectrometry (LA‑ICP‑MS)
Elemental bioimaging and quantification of Au in ex vivo 
placental tissue and in  vitro monolayers was conducted 
by LA-ICP-MS analysis using 15 µm paraffin sections of 
placental tissue or membranes from translocation studies 
stained with hematoxylin/eosin (H&E). The laser ablation 
system LSX-213 G2+ (Teledyne CETAC Technologies, 
Omaha, NE, USA) with a frequency-quintupled Nd:YAG 
laser (213 nm) was coupled to a quadrupole-based ICP-
MS (iCapQc, Thermo Fisher Scientific, Bremen, Ger-
many). To achieve optimal spatial resolution, the smallest 
possible laser spot size of 4 µm was selected. For analy-
sis of ex vivo samples, a scan speed of 12 µm/s and line 
by line ablation with 0  µm space between the lines was 
applied. For smaller in  vitro samples, a scan speed of 
6  µm/s was selected and line by line ablation was con-
ducted with overlapping lines (space between the lines 
of − 2 µm). This oversampling approach resulted in a vir-
tual spot size of 2 µm under quantitative ablation condi-
tions. Both tissue samples were analyzed with a laser shot 
frequency of 20 Hz and the laser energy was adjusted to 
assure quantitative ablation of the samples (9 J cm−2). The 
ablation chamber was flushed with 800  mL/min helium 
carrier gas flow that was mixed with 1.02  L/min argon 
before entering the plasma. The ICP-MS was equipped 
with platinum sampler and skimmer cones and a quartz 
injector pipe with 3.5  mm inner diameter for sample 
introduction. RF power was set to 1550  W and other 
parameters were tuned daily to maximum intensities 
for laser ablation coupling. For analysis of ex  vivo sam-
ples, the isotopes 27Al, 79Br (dwell time 55 ms each), 31P 
and 197Au (110 ms each) were monitored throughout the 
analysis. For in vitro samples, isotopes 79Br (55 ms) and 
197Au (110  ms) were detected. Aluminum and bromine 
were detected as a result of the hematoxylin and eosin 
staining of the sample to obtain an improved allocation 
of tissue features in the microscopic and mass spectro-
metric images, respectively. Due to possible polyatomic 
interferences on the isotopes 27Al, 31P and 79Br, ICP-MS 
analysis was conducted in kinetic energy discrimina-
tion (KED) mode with helium as cell gas at a flow rate of 
4.2 mL/min.
Transient signals were converted into color-coded ele-
mental distribution maps using MassImager software, 
written by Robin Schmid (University of Münster, Karst 
research group). To convert detected signal intensi-
ties into concentrations, quantification was carried out 
by external calibration with matrix-matched standards 
based on 10% gelatin (w/v). Gelatin (100  mg, Grüssing 
GmbH Analytica, Filsum, Germany) was spiked with 
900 µL gold suspensions (0.11–111 µg/g gold) that were 
prepared by dilution of a stock solution of 1000  µg/g 
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gold (CentriPur Merck, Darmstadt, Germany). Mixtures 
were homogenized at 40  °C with frequent shaking. For 
calibration, eight standards with concentrations between 
0.1  µg/g and 100  µg/g were prepared. Approx. 80  µL of 
the mixtures were pipetted onto a sample holder, cooled 
to − 23  °C and sectioned to 15  µm thicknesses using a 
cryomicrotome (CryoStar NX70, Thermo Scientific, 
Waltham, MA, USA). Standard sections were analyzed 
by LA-ICP-MS using the same experimental parameters 
as applied for the tissue sections on the same day. Eleven 
lines per standard concentration were ablated with dura-
tions of 28 s each. While the first line was discarded, the 
signals of the following ten lines were used for quan-
tification. For evaluation of total standard concentra-
tions, 200 mg of each standard were dissolved in 300 µL 
aqua regia. Solutions were mixed with equal amounts of 
arsenic in 6%  HNO3 as internal standard (diluted from 
arsenic ICP standard 1000 µg/g, Merck, Darmstadt, Ger-
many). Aliquots of 5  µL were dried onto quartz glass 
discs (Bruker nano GmbH, Berlin, Germany) and ana-
lyzed by total reflection x-ray fluorescence (S2 Picofox, 
Bruker nano GmbH). The X-ray tube was equipped with 
a molybdenum anode working at an anode current of 
750 μA and voltage of 50 kV. Detection was carried out 
using an energy-dispersive, Peltier-cooled silicon drift-
detector (SDD, XFlash). Signal integration time was set 
to 1000 s. For data evaluation, the software Spectra Pico-
fox Version 7.2.5.0 (Bruker AXS) was used.
Statistics
The experimental data is presented as mean ± standard 
deviation (SD). To identify statistical difference in Au 
distributions in  vitro each compartment was compared 
to the respective control (without cells) or to each other 
(e.g. BeWo vs. HPEC) using an unpaired student’s t-test. 
Statistical significance was obtained when P < 0.05 (*).
Results
Characterization of the AuNPs
The Au-3-PEG and Au-4-COONa NPs have already 
been characterized in a previous study, and results are 
summarized in Table 1 [21]. In addition, zeta potentials 
of Au-3-PEG and Au-4-COONa were measured in EM 
(used for in vitro translocation studies) and PM (used for 
ex vivo translocation studies) and were slightly negative, 
similar to values determined from EM and PM only (data 
not shown).
Colloidal stability of the AuNP suspensions in the dif-
ferent media was investigated by visual observation, 
SAXS and DLS. Suspensions with experimental con-
centrations of the AuNPs (25  µg/mL of Au-3-PEG and 
50  µg/mL Au-4-COOH NPs in EM or  H2O; 25  µg/mL 
of both AuNP types in PM) were incubated for 0 h, 6 h 
(maximum for ex vivo perfusion experiments) and 24 h 
(maximum for in vitro translocation studies) at 37 °C/5% 
 CO2 under static conditions. No pellet formation was 
apparent for Au-3-PEG NPs suspensions in EM, PM or 
 H2O (Fig. 1a, Additional file 1: Fig. S1a, g). In contrast, a 
pellet was observed for Au-4-COONa NPs dispersed in 
EM and PM (Fig. 1d, Additional file 1: Fig. S1d) but not 
in  H2O (Additional file  1: Fig. S1j). Light microscopic 
images of EM and PM suspensions confirmed the forma-
tion of a NP precipitate at the bottom of the well plates 
for Au-4-COONa NPs while no particles were detected 
for Au-3-PEG NP dispersions even after 24 h of incuba-
tion (Additional file  1: Fig. S3). To determine particle/
agglomerate sizes in the soluble NP fraction, SAXS meas-
urements were performed from the supernatant without 
disturbing the pellet. The precipitated fraction was not 
analyzed since the maximum particle size that can be 
detected by SAXS is limited to approximately 100  nm. 
Therefore, DLS was used as a complementary method 
to also detect larger NP agglomerates. SAXS analysis 
revealed that Au-3-PEG NPs dispersed in EM were rela-
tively stable, and only a minor increase in the smaller par-
ticle fraction (r ~ 10–15 nm) and concomitant decrease in 
the larger particle fraction (r ~ 20–30 nm) was observed 
after prolonged incubation for 24  h (Fig.  1c), indicating 
a slight dissociation process. The diameter of gyration 
 (dgyr) slightly decreased over time from 15.7  nm at 0  h 
to 14.1 nm at 24 h, whereas the hydrodynamic diameter 
 (dhyd) obtained with DLS increased from 42.8 nm at 0 h 
to 133 nm at 24 h of incubation at 37 °C (Fig. 1g, Addi-
tional file  1: Fig. S2). For Au-4-COONa suspensions in 
EM, a strong decrease in PDDF was detected over 24 h 
of incubation, which is indicative of particle sedimenta-
tion and lower AuNP concentrations (Fig.  1e, f ). While 
the  dgyr of the suspended particle fraction remained simi-
lar (50.4 nm at 0 h vs. 46.8 nm at 24 h), a major decrease 
was observed in the  dhyd (902.1  nm at 0  h, 642.5  nm at 
6 h and 61.9 nm at 24 h) (Fig. 1g, Additional file 1: Fig. 
S2). This was accompanied by a substantial decrease of 
the average scattered intensity of light from 1707.4 kcps 
at 0 h to 87.3 kcps at 6 h and to 57.3 kcps at 24 h (derived 
count rates) measured by DLS over 24 h. Taken together, 
this indicates that Au-4-COONa NPs quickly agglom-
erate in EM, with bigger particles leaving the detection 
window due to sedimentation. In PM, similar colloidal 
stability was observed as in EM (Additional file  1: Fig. 
S1). Au-3-PEG NPs showed a minor decrease of  dgyr from 
13.4 nm at 0 h to 10.8 nm at 6 h and of  dhyd from 21 nm 
at 0 h to 18.1 nm at 6 h, respectively (Fig. 1g, Additional 
file 1: Fig. S2). For Au-4-COONa NPs in PM, the amount 
of particles was reduced after 6 h (Additional file 1: Fig. 
S1e, f ) and the  dgyr decreased from 30.2  nm at 0  h to 
21.0 nm at 6 h (Fig. 1g). The  dhyd of Au-4-COONa NPs 





















































































Fig. 1 Colloidal stability of Au‑3‑PEG (a–c) and Au‑4‑COONa (d–f) NPs in EM. a, d Au‑3‑PEG and Au‑4‑COONa NP suspensions in EM (19.2 μg/mL Au 
each) after 0, 6 and 24 h of static incubation (37 °C/5%  CO2) in the absence of cells. b, e Scattering intensity as function of scattering vector q and c, 
f pair distance distribution function (PDDF) of the PEGylated and carboxylated AuNPs in EM. g Diameter of gyration  (dgyr; mean ± error) calculated 
from SAXS data and hydrodynamic diameter from DLS analysis  (dhyd; Z‑Average)
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in PM was 621.3  nm at 0  h (1745.9  kcps) and 1634  nm 
after 6  h (1186.5  kcps) of incubation, revealing particle 
agglomeration (Fig. 1g, Additional file 1: Fig. S2). In con-
trast to Au-4-COONa dispersions in EM, an increase in 
 dhyd was observed suggesting that in PM these particles 
agglomerate more slowly and therefore do not readily 
leave the detection window in DLS. In water, both AuNPs 
appeared to stay in suspension (Additional file  1: Figs. 
S1, S2). Au-3-PEG NPs demonstrated a slight increase 
of  dgyr, (19.9 nm at 0 h vs. 25.4 nm at 24 h) but a small 
decrease of  dhyd over time (46.28 nm at 0 h vs. 32.66 nm 
at 24 h), respectively (Fig. 1g). In contrast to EM or PM, 
Au-4-COONa NPs displayed a high colloidal stability in 
water, as evidenced by highly stable signal intensities dur-
ing SAXS measurements (Additional file  1: Fig. S1k, l) 
and a minimal decrease in  dgyr (45.6 nm at 0 h vs. 40.2 nm 
at 24 h) and  dhyd (142 at 0 h vs. 94.4 nm at 24 h; Fig. 1g).
Determination of AuNP distribution using a static in vitro 
co‑culture placental barrier model
To ensure the absence of acute toxicity, cell viability was 
assessed prior to the translocation studies. Exposure 
of BeWo cells for up to 48 h with AuNP concentrations 
ranging from 0 to 50 µg/mL did not affect their viability 
(Additional file 1: Fig. S4).
In vitro placental translocation studies were performed 
across tight layers of trophoblast cells (BeWo) only, pla-
cental microvasculare endothelial cells (HPEC) only or 
the co-cultures (BeWo/HPEC) in static conditions. To 
allow for direct comparison of the NPs containing dif-
ferent amounts of Au, cell cultures were exposed to the 
same Au content, namely 19.2  µg Au/mL (correspond-
ing to 25 µg/mL Au-3-PEG and 50 µg/mL Au-4-COONa 
NPs). ICP-MS measurements revealed that around 54.2% 
and 17.8% of Au from Au-3-PEG and Au-4-COONa NPs 
were able to cross the cell-free microporous membrane 
(Fig.  2), corresponding to concentrations of 4.40  µg/mL 
Au-3-PEG NPs and 2.82  µg/mL Au-4-COONa NPs. Of 
note, an equilibrium of the AuNP concentrations would 
be reached when three quarters of the added NP amount 
would reach the basolateral chamber [which is 75% of the 
initial dose (ID)], since apical and basolateral volumes in 
the bi-chamber system are 0.5 and 1.5 mL, respectively. 
Au-3-PEG and Au-4-COONa NPs were highly retained 
by the HPEC and BeWo monolayer as well as the co-cul-
ture even after 24 h of exposure. Only 1.3, 3.6 and 0.6% of 
the ID of Au-3-PEG NPs and 0.2, 0.1 and 0.1% of the ID 
of the Au-4-COONa NPs were detected on the basolat-
eral side of BeWo and HPEC monolayers or co-cultures, 
respectively. Significant differences in the retention capa-
bility of the distinct cell layers were only observed for the 
HPEC layer, which was more permeable to Au-3-PEG 
NPs as compared to the BeWo or co-culture layers. Only 
approximately 80% of the ID of the carboxylated AuNPs 
was found by ICP-MS measurements, indicating a poten-
tial adsorption to the insert holder and/or loss of precipi-
tated particles during washing of the membrane (addition 
of fresh medium for TEER measurements).
When analyzing the Au content in the membrane 
fraction, only very low amounts of Au-3-PEG NPs were 
detected (0.5, 0.3, 0.2% of the ID) in BeWo, HPEC and 
co-cultures, respectively. In contrast, almost all Au-
4-COONa NPs were found to be internalized by the cells 
and/or adsorbed on the cell surface in BeWo monolay-
ers (77.4% of ID), HPEC monolayers (61.4% of ID) and 
co-cultures (71.2% of ID). Au content in cell free mem-
branes were 0.3% of ID for Au-3-PEG NPs and 16.5% 
of ID for Au-4-COONa NPs. Overall, Au-3-PEG and 
Au-4-COONa NPs demonstrate a substantially different 
in  vitro distribution behavior, which was confirmed by 
LA-ICP-MS (Fig. 3).
Mean Au concentrations of 1370  µg/g and 0.6  µg/g 
were detected in the co-culture layers after Au-4-COONa 
and Au-3-PEG NP treatment for 24 h, respectively. While 
most AuNPs were detected evenly distributed in the 
BeWo cell layer, only low signals were measured in the 
membrane and the HPEC layer. TEM micrographs fur-
ther verified the uptake of Au-4-COONa NPs in BeWo 
cells, and particles were mainly located in membrane-
bound vesicles in the form of small agglomerates (Fig. 4). 
In contrast, no NPs were observed in BeWo cells exposed 
to Au-3-PEG NPs for 24 h (Additional file 1: Fig. S6). For 
each translocation experiment, transepithelial electrical 
resistance (TEER) was measured before and after AuNP 
exposure. TEER values were slightly decreased only after 
Au-4-COONa NP treatment of the BeWo cell layer and 
the co-culture (Additional file 1: Fig. S5).
Determination of AuNP distribution in the ex vivo placenta 
perfusion model
Placental translocation of Au-3-PEG and Au-4-COONa 
NPs was determined using the ex  vivo perfusion of 
term placental tissue. Here, a concentration of 25  μg/
mL AuNPs was used for both, the PEGylated and car-
boxylated AuNPs. As shown in Fig.  5a, similar trans-
location kinetics of Au-3-PEG and Au-4-COONa NPs 
were observed during 6 h of perfusion. The AuNP con-
centration decreased from 25  μg/mL to 13.76  μg/mL 
and 10.45  μg/mL of Au-3-PEG and Au-4-COONa NPs, 
respectively. Both, Au-3-PEG NPs and Au-4-COONa 
NPs, were found to accumulate to a similar amount in 
placental tissue after 5–6 h of perfusion (4–7 μg/g tissue 
for Au-3-PEG NPs vs. 2–14 μg/g tissue for Au-4-COONa 
NPs). No or very low translocation to the fetal side was 
observed for Au-4-COONa and Au-3-PEG NPs (0 and 
0.0031  μg/mL after 6  h; n = 2), respectively. To assess 
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adsorption of the AuNPs to the perfusion device, control 
perfusions were done in the absence of placental tissue 
(Additional file  1: Fig. S7). These experiments demon-
strated that Au-3-PEG NPs stayed in suspension over 6 h 
of perfusion, whereas the Au-4-COONa NP concentra-
tion dropped after around 3  h of perfusion, indicating 
sedimentation or binding of these AuNPs to the tubes 
and/or system components. Therefore, LA-ICP-MS 
analysis was only performed from placental tissue before 
and after 6  h of perfusion with Au-3-PEG NPs (Fig.  6). 
Around 7.9  µg Au/g tissue was found within 79Br bor-






















































































Fig. 2 Au distribution in the static in vitro placental barrier model after exposure to Au‑3‑PEG and Au‑4‑COONa NPs for 24 h. Control membranes, 
monocultures or co‑cultures were exposed to 19.2 μg/mL Au from Au‑3‑PEG and Au‑4‑COONa NPs for 24 h and Au content was determined in 
apical and basolateral supernatants as well as in the membrane fraction using SF‑ICP‑MS. Distribution of the Au amount as % of the initial dose (ID; 
a) and absolute concentrations of the AuNPs (b) in the apical and basolateral chamber and in the membrane fraction, respectively. The latter were 
calculated from the Au concentrations measured by SF‑ICP‑MS using the relative Au content of the NPs determined with ICP‑OES (see Table 1). 
Data represent the mean ± SD of 3–4 biologically independent experiments with one technical replicate each. P‑value below 0.05 are considered 
statistically significant (*, x and + are related to apical, membrane and basolateral values)
Page 10 of 16Aengenheister et al. J Nanobiotechnol  (2018) 16:79 
in the outer layer of the placental tissue, namely the ST, 
but were also able to penetrate into the placental tissue. 
Few detached ST fragments with high Au signals were 
observed. However, such CK7-positive fragments were 
already present before perfusion with AuNPs or after 6 h 
perfusion with PM only (Additional file 1: Fig. S8).
Discussion
Choice of AuNPs and placenta models
Small 3–4 nm AuNPs were selected for this study since 
placental transfer appears to inversely correlate with par-
ticle size [6] and considerably increased translocation 
rates have been reported for AuNPs smaller than approx. 
10  nm at the alveolar epithelial tissue barrier [18]. To 
exploit the impact of different surface modifications on 
placental translocation, PEGylated and carboxylated 
AuNPs were included. Since PEGylation is known to 
reduce NP-cell and NP–protein interactions, less accu-
mulation in placental tissue was expected compared to 
carboxylated AuNPs [29].
Relatively high concentrations of 25–50 µg/mL AuNPs 
were chosen, which are representative of a medically 
relevant exposure scenario where blood concentrations 
up to 100  μg/mL are conceivable [30]. Environmental 
exposure of pregnant women to AuNPs released from 
consumer products or nanomedical applications to the 
environment is currently expected to be very low [31] 
and outer tissue barriers such as the lung, skin or intes-
tine have been shown to greatly limit NP transfer to the 
systemic circulation [18, 32].
The ex vivo perfusion of human term placental tissue is 
considered as gold standard for human placental trans-
location studies since it retains the structural complexity 
and recapitulates the dynamic environment of the in vivo 
tissue. However, perfusion studies are limited to a few 
hours, have a low success rate (approx. 30%) and pro-
vide limited mechanistic insights [9, 26]. Consequently, 
in  vitro transfer models based on microporous sup-
ports are frequently used as a complementary approach 







































e f g h





Fig. 3 Distribution of Au‑4‑COONa and Au‑3‑PEG NPs in the in vitro placental barrier model after 24 h. Co‑cultures were exposed to 19.2 μg/mL 
Au from Au‑4‑COONa (a–d) and Au‑3‑PEG (e–h) NPs for 24 h under static conditions. A co‑culture without NP treatment was used as negative 
control. H&E staining of 5 µm thick sections of the co‑culture enables allocation of Au signals (a, e, i; adjacent sections to those for LA‑ICP‑MS). 
Elemental distribution of 79Br to visualize cell structure (b, f, j). 197Au was measured to localize Au (c, g, k). Overlay of 79Br and 197Au to co‑localize Au 
signals in cells (d, h, l). Elemental distribution map of 79Br and 197Au is represented in signal intensities and Au concentrations (black: minimum, red: 
maximum), respectively. Images were obtained from one independent experiment
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to address permeability across individual cell layers [25, 
33–35]. Here, we applied our recently developed human 
placental co-culture model to investigate translocation 
across the trophoblast layer (BeWo cells), endothelial 
layer (HPEC) or the co-culture [25]. It has been shown 
that the translocation rates of small molecules obtained 
using these cell- and tissue-based models are in good 
correlation with each other and that ex  vivo transloca-
tion rates predict relatively well the in vivo situation [36, 
37]. However, the predictive value of these models for NP 
translocation studies remains to be proven [6, 34].
Colloidal stability of AuNPs in biological media
If NPs are added to a biological matrix, constituents like 
proteins and lipids can adhere to the particles, forming 
a so-called bio- or protein corona [38–40]. This can lead 
to an agglomeration of the particles followed by sedi-
mentation and thereby alter their interaction with cells 
[41]. Since the formation of a corona is highly depend-
ent on the properties of the NP and the composition of 
the media, we examined potential agglomeration and 
sedimentation of both AuNP types in  H2O, EM (in vitro) 
and PM (ex vivo) by visual inspection as well as SAXS 
and DLS measurements. In water, both AuNPs stayed 
in suspension after 24  h incubation at 37  °C without a 
substantial size change. High colloidal stability was also 
observed for Au-3-PEG NPs dispersed in PM and EM, 
demonstrating the ability of PEG to restrict protein NP 
interactions [29]. In contrast, strong agglomeration was 
observed for Au-4-COONa NPs in PM and EM. How-
ever, limitations of the SAXS and DLS approaches ham-
per the identification of exact particle sizes. In SAXS, the 
observation window is weighted towards particles below 
its detection limit (~ 100  nm) while in DLS (due to the 
larger wavelength of lasers with respect to X-ray), the sig-
nal is more weighted by larger particles. Therefore, SAXS 
analysis can indicate precipitation of agglomerated parti-
cles due to intensity loss in the supernatants, while DLS 
measurements can detect larger NP agglomerates but 
fails in giving exact particle sizes for polydisperse sam-
ples [42]. A possible explanation for the agglomeration 
of Au-4-COONa but not Au-3-PEG NPs may be a partial 
loss of the stabilizing carboxyl-ligand since thiol-ligands 
can be released from AuNPs in particular in in vivo set-
tings. In a previous work it has been shown that AuNPs 
functionalized with thiol-ending PEG were most sta-
ble in aqueous solutions compared to other thiol-com-
pounds [43]. Although colloidal stability of the AuNPs 
was investigated in the relevant biological media and for 
the same incubation times as in the experimental setup, 
we cannot exclude that the agglomeration behavior of 
the AuNPs may be slightly different under experimen-
tal conditions in the presence of cells/tissue or dynamic 
exposure conditions. Indeed, we observed that almost 
all Au-4-COONa NPs adhered to the ex  vivo perfusion 
device in an empty perfusion already after 3 h of perfu-
sion, whereas a considerable amount of NPs remained 












Fig. 4 Uptake of Au‑4‑COONa NPs in BeWo cells after 24 h. a TEM micrographs showing an overview of two BeWo cells. Two different locations 
with internalized AuNPs (white squares b and c) are presented at higher magnifications (b, b’ and c, c’)
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of placental tissue (Fig. 5a and Additional file 1: Fig. S7). 
Proteins released from the placental tissue and/or the 
slightly different pressure conditions may account for the 
observed differences.
Placental translocation of AuNPs in vitro
Translocation studies revealed that Au-3-PEG and Au-
4-COONa NPs could pass the in  vitro co-culture pla-
cental barrier in low amounts after 24  h of exposure 
(0.6% and 0.1% of the ID, respectively). Although these 
values were low, the determined Au concentrations 
were clearly above the detection limit of the ICP-MS 
analytics (0.014% of the ID for both AuNPs). Both, the 
trophoblast and endothelial cell layer exhibited a high 
barrier capacity for Au-4-COONa NPs while for Au-
3-PEG NPs, the endothelial cell layer showed a lower 
retention potential than the trophoblast layer. Although 
both AuNPs were not cytotoxic to BeWo cells at con-
centrations of 50  µg/mL for up to 48  h of exposure, a 
small decrease in the TEER was noted after transloca-
tion studies with Au-4-COONa NPs for 24 h indicating 
a potential loss in barrier integrity. Whether this slight 
decrease in TEER value is sufficient to allow penetration 
of small molecules or even NPs as well as the long-term 
consequences of carboxylated AuNP accumulation 
on barrier integrity need to be carefully addressed in 
future studies. No impact on TEER was observed after 





































Fig. 5 Perfusion kinetics and placental tissue accumulation of Au‑3‑PEG and Au‑4‑COONa NPs determined by SF‑ICP‑MS. a Maternal and fetal 
AuNP concentration over time (data presented as mean ± SD). AuNP concentrations were calculated from the Au concentrations measured 
with SF‑ICP‑MS using the relative Au content of the NPs determined with ICP‑OES (see Table 1). b Placental tissue accumulation of Au‑3‑PEG and 
Au‑4‑COONa NPs after 5–6 h of perfusion, shown as Au and AuNP concentration (calculated as indicated before)
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in this case, particle transfer across an intact co-culture 
barrier was possible.
Interestingly, a slightly higher transfer was found for 
Au-3-PEG NPs despite the fact that deposited doses 
were probably lower compared to Au-4-COONa NPs 
due to their strong agglomeration in the culture medium. 
Indeed, substantial amounts of Au-4-COONa NPs were 
detected in the membrane fraction by ICP-MS and pre-
dominantly localized to the trophoblast layer as evi-
denced by LA-ICP-MS. Since conventional ICP-MS 
and LA-ICP-MS cannot discriminate between ionic and 
particulate Au, TEM analysis was employed to confirm 
cellular uptake of Au-4-COONa NPs. Small nanosized 
but no microsized agglomerates of Au-4-COONa NPs 
were observed in membrane-bound vesicles. There-
fore, agglomeration may at least partially account for the 
reduced translocation compared to well-dispersed Au-
3-PEG NPs. No particles or agglomerates were observed 
in TEM micrographs of BeWo cells exposed to Au-3-PEG 
NPs possibly due to the very low amounts of internal-
ized Au-3-PEG NPs as evidenced by SF-ICP-MS and 
LA-ICP-MS.
This differential uptake and accumulation behavior of 
Au-3-PEG and Au-4-COONa NPs observed in the co-
culture transfer model was highly similar to the findings 
described in our previous study using 3D placental co-
culture MTs [21]. Au-4-COONa NPs were internalized 
in higher amounts than Au-3-PEG NPs and accumulated 
mostly in the outer BeWo cell layer of the MT. Further-
more, studies with placental co-culture MTs provided 
additional information on the ability of AuNPs to pen-
etrate into the fibroblastic core after crossing the troph-
oblast barrier, which is more difficult to obtain in the 
in  vitro co-culture transfer model due to the presence 
of an artificial microporous membrane and challenges 
to detect the NPs in the delicate endothelial cell layer. 
In placental MTs it has been shown that internalized 
Au-3-PEG NPs crossed the BeWo layer and penetrated 
into the fibroblastic core of the MTs [21], whereas in the 
in  vitro placental transfer model, internalization of Au-
3-PEG NPs by endothelial cells was unclear due to the 
low resolution limit of the LA-ICP-MS technique (2 μm). 
Therefore, the combination of these two in vitro placen-
tal models can deliver complementary insights into NP 
uptake and translocation at the placental barrier.
Placental translocation of AuNPs ex vivo
Although, the outcomes obtained with the placental MT 
and the co-culture transfer model are fairly consistent, 
these in vitro approaches have some limitations. In both 
models, the BeWo cell line was used to mimic the ST bar-
rier. While the ST forms a syncytium in vivo, BeWo cells 
do not fuse spontaneously and consist mainly of undif-




























Fig. 6 Distribution of Au‑4‑PEG NPs in placental tissue after 6 h of perfusion. Placental tissue was perfused with 25 μg/mL Au‑3‑PEG NPs for 6 h. 
a, e H&E staining of placental tissue before (a) and after perfusion (e). b, f Elemental distribution of 79Br to visualize tissue structure. c, g 197Au 
was measured to localize Au. d, h Overlay of 79Br and 197Au to co‑localize Au signals in placental tissue. Elemental distribution map of 79Br and 
197Au is represented in signal intensities and Au concentrations (black: minimum, red: maximum), respectively. Images were obtained from one 
independent experiment
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cells. A further shortcoming is the lack of a physiologi-
cal microenvironment, since both in  vitro studies were 
conducted under static conditions. However, a dynamic 
model could be crucial for reliable NP studies [6] since 
NPs exhibit unique agglomeration and sedimentation 
behavior in biological media that can have a significant 
impact on the bioavailable dose [22, 23]. Moreover, flow 
conditions may further affect cellular doses, transport 
kinetics of NPs as well as cell performance as shown in 
recent studies, where dynamic models were capable of 
producing more predictive doses and accurate outcomes 
compared to static systems [24, 44]. Therefore, we addi-
tionally investigated translocation kinetics of Au-3-PEG 
and Au-4-COONa NPs using the dynamic ex  vivo pla-
centa perfusion model. Similar to the in  vitro studies, 
AuNP translocation was limited, and a slightly higher 
transfer was observed for Au-3-PEG (0.01% of ID; detec-
tion limit: 0.0052% of ID) compared to Au-4-COONa 
NPs, which did not cross the placental barrier after 5–6 h 
of perfusion (detection limit: 0.0085% of ID). However, 
due to the considerable agglomeration of Au-4-COONa 
NPs in PM and non-specific adherence to the perfusion 
system, the available cellular doses are likely much lower 
than for perfusions with Au-3-PEG NPs or experiments 
in the static in vitro models. Dosimetry issues may also 
explain why AuNP tissue concentrations were similar 
in ex  vivo perfusion studies while much higher cellular 
uptake was detected for Au-4-COONa NPs in the static 
in vitro models. According to LA-ICP-MS analysis, Au-
3-PEG NPs penetrated and distributed throughout the 
placental tissue, which has also been described in 3D 
placental MTs [21]. In few cases, ST fragments were 
observed that appeared to accumulate slightly larger 
amounts of Au-3-PEG NPs than the intact ST layer, pos-
sibly due to a higher available surface area of these frag-
ments. ST fragments were already present before the 
perfusion with NPs, excluding major adverse effects of 
AuNPs on ST barrier integrity. Moreover, no leakage was 
observed during 6 h of perfusion, which further supports 
placental barrier tightness. It is possible that these frag-
ments were already present in the placental tissue after 
delivery or they may represent an artefact from sample 
processing for histological analysis.
Overall, in vitro and ex vivo placental transfer models 
delivered fairly consistent and complementary results on 
the relative uptake and translocation of Au-3-PEG and 
Au-4-COONa NPs when accounting for differences in 
particle stability and non-specific adherence to the test 
system. Nevertheless, a direct comparison is challeng-
ing due to differences in deposited AuNP concentrations, 
culture media and/or duration of exposure. For stable 
NPs such as Au-3-PEG NPs, low placental translocation 
in  vitro and ex  vivo correlates well with findings from 
placental translocation studies in rodents [14, 15].
Conclusions
In this study, we provide the first evidence for the trans-
location of small 3–4 nm AuNPs across the human pla-
cental barrier both in  vitro and ex  vivo. Although only 
very low percentages of the applied doses did cross the 
placental barrier, this still represents a considerable num-
ber of individual particles. Since the developing fetus 
is particularly vulnerable to toxic substances, poten-
tial embryo-fetotoxic and teratogenic effects of AuNPs 
should be carefully investigated. However, as our mod-
els represent the final stages of pregnancy, it remains to 
be shown if small AuNPs can also cross the early human 
placental barrier. So far, it is unclear if the embryo is bet-
ter or less protected against effects of NP exposure dur-
ing early versus later stages of pregnancy (as reviewed by 
Juch et al. [45]). In general, it is assumed that NP translo-
cation across the placental barrier is lower during early 
pregnancy due to the increased thickness of the placen-
tal barrier, but, substantial accumulation and persistence 
of AuNPs in placental tissue could interfere with proper 
placental development and function. For instance, we 
observed a decrease in TEER after exposure to carboxy-
lated AuNPs suggesting that barrier integrity may be 
compromised. In addition, studies in pregnant rodents 
provide increasing evidence that NPs can damage the 
placental barrier or alter the release of placental media-
tors which may at least partially account for the observed 
fetotoxic effects [46–50].
To support the safe and sustainable use of AuNPs, we 
should seek to understand if AuNPs impact on human 
placental function thereby causing a hostile gestational 
environment for fetal growth, development and matu-
ration. Finally, to more clearly elucidate the impact of 
different NP properties and modifications on placental 
uptake and translocation, NPs with high stability in bio-
logical media are needed to exclude a superimposed size-
dependent effect.
A prerequisite to achieve novel insights on NP-placenta 
interactions is a thorough NP characterization as well 
as the use of predictive human placenta models. In this 
regard, our study suggests that results on AuNP placen-
tal tissue accumulation as well as placental translocation 
obtained with human in vitro and ex vivo placenta mod-
els correlate well with each other and with rodent studies. 
However, careful assessment of NP stability and non-spe-
cific interference with the test system is indispensable for 
the proper interpretation of the results and for compari-
son between different models.
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Additional file
Additional file 1: Fig S1. Colloidal stability of Au‑3‑PEG and Au‑4‑COONa 
NPs in PM and ultrapure water. Fig S2. Size distribution of Au‑4‑COONa 
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